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Background: Plantar fibromatosis is a benign disease creating nodules on the medial plantar side of affected
patients. While surgical removal is regarded as the therapeutic mainstay, recurrence rates and impairment of
daily activities remains substantial. High-energy focussed extracorporeal shockwave therapy has been suggested
to be potentially effective in plantar fibromatosis in terms of pain reduction.
Hypothesis: High-energy focussed extracorporeal shockwave therapy reduces pain in plantar fibromatosis.
Findings: A total number of six patients (5 males, 58±4 years) were included with plantar fibromatosis
(Ledderhose’s disease) associated with pain. Three patients were operated on previously, one had concomitant
Dupuytren’s contracture. High-energy focussed ESWT was applied using a Storz Duolith SD1 (2000 impulses, 3 Hz,
1.24 mJ/mm2) in two sessions with 7 days between. Pain was 6±2 at baseline, 2±1 after 14 days and 1±1 after
3 months. Softening of the nodules was noted by all patients. No adverse effects were noted.
Conclusions: High-energy focussed extracorporeal shockwave energy reduces pain in painful plantar fibromatosis
(Morbus Ledderhose). Further large-scale prospective trials are warranted to elucidate the value of high-energy
focussed extracorporeal shockwave therapy (ESWT) in plantar fibromatosis in terms of recurrence and efficacy.
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Plantar fibromatosis is named after the German surgeon
Prof. Dr. Georg Ledderhose following his report on a
Dupyutren-like disease of the foot sole in 1897. As it is
the case for Dupuytren’s disease of the palm, aetiology
remains largely unknown to date [1]. A familiar dispos-
ition might account for a higher risk. Furthermore,
patients suffering from Dupuytren’s contracture may
simultaneously present with plantar fibromatois, knuckle
pads on the dorsum of the fingers and penile fibromato-
sis (Peyronie’s disease).
Similar to Dupuytren’s disease of the hand, where in
early stages nodules are evident, plantar fibromatosis
yields 1-2cm nodules located typically on the medial side
of the foot arch. Therapeutically, radiotherapy as well as* Correspondence: knobloch.karsten@mh-hannover.de
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distribution, and reproduction in any mediumsurgery have been applied in a number of cohort studies
and case series with inconsistent results. A cohort study
from the Netherlands reported on 27 patients with plan-
tar fibromatosis who underwent 40 operations on 33
feet [2]. The overall recurrence rate was 60%. Combin-
ing surgery and radiotherapy was studied in another
report. However, as stated by the authors, radiotherapy
was associated with a significantly impaired functional
status in 50% of the patients [3]. A German cohort re-
port with 25 patients found 44% less nodules 38months
following 30Gy radiotherapy [4]. Besides, pain was
reduced in 60% of the patients. Adverse effects reported
were dry skin and slight erythema following radiotherapy.
To date, the role of alternative therapeutic options in
Ledderhose’s disease is undetermined.
Penile fibromatosis referred to as Peyronie’s disease
affects middle-aged men between 40 and 60 years with
penile pain, curvature during erection and potentially
erectile dysfunction. Extracorporeal shockwave therapyCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Plantar fibromatosis as Ledderhose’s disease in a
bilateral setting in a male patient with concomitant severe
bilateral Dupuytren’s contracture.
Figure 2 High-energy focussed extracorporeal shockwave
therapy (ESWT, Storz Duolith SD1) in plantar fibromatosis
(Ledderhose’s disease).
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to destroy kidney stones, has been tested in penile fibro-
matosis (Evidence level Ib) [5]. Another study reported
that about half of all ESWT treated patients had a signifi-
cant reduction in penile angulation [6]. Given these
observations in penile fibromatosis, we started to perform
a randomized-controlled trial to evaluate high-energy
focussed ESWT in palmar fibromatosis, Dupuytren’s con-
tracture (DupuyShock) [7].Figure 3 Pain daily log during two high-energy focussed ESWT sessioGiven the similiarities of penile and plantar fibromato-
sis in a histological and clinical perspective, we sought
to evaluate the effects of high-energy focussed ESWT on
plantar fibromatosis in a pilot series, which is presented
herein.
Research hypothesis
Given the aforementioned effect in penile fibromatosis,
we hypothesize that high-energy focussed extracorporealns at day 0 and day 7.
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fibromatosis (Ledderhose’s disease).
Methods
High-energy focussed ESWT was applied without
anesthesia using a Storz Duolith SD1 device in two
therepeutic sessions with a week interval in between
with the following settings (Figures 1 and 2):
 Number of shockwaves: 2000 impulses
 Frequency: 3 Hertz
 Energy flux density 1.24 mJ/mm2
Patients were allowed to walk or sport following
ESWT therapy. All patients documented pain in the
morning on a visual analogue scale (VAS 0–10) on a
daily basis.
Results
A total number of six patients (5 males, 58±4 years)
were included with plantar fibromatosis associated with
pain. Three patients were operated on before. High-
energy focussed ESWT was applied using a Storz
Duolith SD1 (2000 impulses, 3 Hz, 1,25 mJ/mm2) for 1–3
sessions. Pain was 6±2 at baseline for at mean 4±2
months and 2±1 after 14 days (p<0,05, Figure 3). At
three months follow-up, pain was 1±1. Softening of the
nodules was noted by all patients. No adverse effects
were noted. We found no meaningful difference in the
outcome of Ledderhose patients with or without previ-
ous plantar surgery.
Conclusion
High-energy focussed extracorporeal shockwave energy
reduces pain in painful plantar fibromatosis. Further
large-scale prospective trials are warranted to elucidate
the value of high-energy focussed extracorporeal shock-
wave therapy in plantar fibromatosis in terms of recur-
rence and efficacy.
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